FDA cites two European companies in separate warning letters

lab

The FDA named two European drug manufacturers--Delarange Cosmetics & Healthcare of the Netherlands and Wallace Cameron of the U.K.--in separate warning letters, citing poor quality control, filthy equipment and failure to register with the agency.

In the case of Delarange, the FDA said in a warning letter recently posted on its website that during an inspection that ran from May 30 to June 3 of its facility in Zeewolde, it found the firm wasn’t testing its finished products and wasn’t using a quality control unit to review and approve the release of its drugs.

Additionally, inspectors found Delarange wasn’t properly cleaning the equipment, which could result in product contamination.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

As for Wallace Cameron, located in Wishaw, Scotland, the regulatory agency scolded the firm for failing to register and list its products with the FDA.

“Our records indicate that you have not registered your establishment for 2016, but have continued to manufacture, prepare, propagate, compound, or process drugs that were not listed but being imported or offered for import into the United States during this time,” the agency says in its warning.

The drug manufactured at Wallace Cameron wasn’t mentioned by the agency.

- here’s the Delarange warning letter
- check out the Wallace Cameron warning letter

Related Article:
FDA slaps CordenPharma EU plant with warning letter

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.